IP Library Granted Patent US 7,459,479
Granted Patent B2
US 7,459,479 · App. 11/683,534 · Granted Dec 2, 2008

Benzylated PDE4 inhibitors

Assignee: Biolipox AB
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,459,479
App. No.
11/683,534
Granted
Dec 2, 2008
Kind
B2
Abstract

The present invention is directed to a method for reducing the emetogenic effects of PDE inhibitors, and more particularly is directed to compounds having PDE4 inhibition activity with little or no emetogenic side-effects, and chemical methods including benzylation for preparing such compounds. A benzyl group may be attached to either a carbon or nitrogen atom of a PDE4 inhibitor. Suitable benzylation chemistry is to extract a hydrogen from a PDE4 inhibitor, preferably with a base, and then react the resulting nucleophilic PDE4 inhibitor with a benzylating agent, e.g., benzyl bromide or a derivative thereof.

Claims (5)

1. A compound having the following formula:

wherein:

Bzl is a benzyl group of the formula

wherein each of the numerals 1, 2, 3, 4 and 5 is carbon, with the proviso that the ring is aromatic; and

n is 5 and R 1 at each occurrence is independently selected from halogen, nitro, R 2 , and OR 2 wherein and R 2 at each occurrence is independently selected from H, C 1 -C 8 alkyl, alkoxyalkyl having 3-7 carbons in the alkoxy portion and 2-4 carbons in the alkyl portion, phenoxyalkyl having 2-6 carbons in the alkyl portion, C 3 -C 7 cycloalkyl, C 6 -C 9 polycycloalkyl, alkylcycloalkyl, hydroxyalkyl, carboxylate, alkylcarboxylate, carboxyl, alkyl carboxyl, amide, alkylamide, phenyl, phenylalkyl having 1-8 carbons in the alkyl portion, phenylaminoalkyl having 2-6 carbons in the alkyl portion and the amino may be optionally substituted with C 1 -C 4 alkyl and indanyl; wherein the alkyl portion of an R 2 group may be optionally substituted with one or more fluorine atoms, hydroxyl or C 1 -C 8 alkoxy; and the phenyl portion of an R 2 group may be optionally substituted with C 1 -C 8 alkyl, C 1 -C 8 alkoxy or halogen.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2008
From: INFLAZYME PHARMACEUTICALS LTD.
To: BIOLIPOX AB
Reel/Frame 020601/0878 →
Continuity (4)
Continuation 1039168500 · Mar 18, 2003
Division 0981008500 · Mar 16, 2001
Provisional Application 6019033700 · Mar 16, 2000
Related Publication 20070208181A1 · Sep 6, 2007